Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

iOnctura SA bags €15m in Series A round

The Series A round was led by Dutch investor INKEF Capital, and Swiss VI Partners  AG and Zurich-based investor Schroder Adveq as new...

Royal DSM acquires Glycom A/S for €765m

The Dutch industry giant for nutrition, health and sustainable products paid €765m for Glycom A/S, which made €74m of sales in 2019, mainly from a...

New stromal target overcomes cancer resistance

According to Eugene Park at University of Cambridge and colleagues, the treatments, which undercut pathways in the tumour microenvironment that...

Nestlé heavily invests in sustainable packaging

According to the announcement and building on its 2018 commitment to make 100% of its packaging recyclable or reusable by 2025, Swiss food giant...

Hydrogel fights wound infection and inflammation

The new gel mimics the body’s natural defenses to tackle both inflammation and bacterial infection – two major concerns for patients recovering from...

Merck and 4SC collaborate in immunooncology

Under the agreement, 4SC AG will sponsor clinical testing of a combination of its oral class I histone deacetylase (HDAC) blocker domatinostat (HDAC...

UK researchers present dengue virus transmission map

The map of variation in dengue transmission intensity rather than current maps of endemicity offers clues about the most effective types of...